Zaylan Associates

Over the next 5-10 years, the biopharma industry is poised to invest hundreds of millions of dollars in “Lab of the Future” (LoF) or “Digital Labs” initiatives, with digital spending expected to surge from $4 billion to $10 billion.

Single Cell Genomics is one of the most attractive high growth segments of life sciences research. Since the dawn of genomics, samples have been analyzed in bulk,

Liquid biopsy is one of the most exciting new developments in life sciences. In cancer and in the area of NIPT (non-invasive prenatal testing), one significant limitation was gaining access to appropriate tissue biopsy from patient in order to perform pathological testing.